Dracorhodin perchlorate inhibits osteoclastogenesis through repressing RANKL-stimulated NFATc1 activity

Yuhao Liu, Ziyi Wang, Chao Ma, Zhenquan Wei, Kai Chen, Chao Wang, Chi Zhou, Leilei Chen, Qingwen Zhang, Zhenqiu Chen, Wei He, Jiake Xu

Research output: Contribution to journalArticlepeer-review

16 Citations (Scopus)


Osteolytic skeletal disorders are caused by an imbalance in the osteoclast and osteoblast function. Suppressing the differentiation and resorptive function of osteoclast is a key strategy for treating osteolytic diseases. Dracorhodin perchlorate (D.P), an active component from dragon blood resin, has been used for facilitating wound healing and anti-cancer treatments. In this study, we determined the effect of D.P on osteoclast differentiation and function. We have found that D.P inhibited RANKL-induced osteoclast formation and resorbed pits of hydroxyapatite-coated plate in a dose-dependent manner. D.P also disrupted the formation of intact actin-rich podosome structures in mature osteoclasts and inhibited osteoclast-specific gene and protein expressions. Further, D.P was able to suppress RANKL-activated JNK, NF-κB and Ca2+ signalling pathways and reduces the expression level of NFATc1 as well as the nucleus translocation of NFATc1. Overall, these results indicated a potential therapeutic effect of D.P on osteoclast-related conditions.

Original languageEnglish
Pages (from-to)3303-3313
Number of pages11
JournalJournal of Cellular and Molecular Medicine
Issue number6
Publication statusPublished - 1 Mar 2020


Dive into the research topics of 'Dracorhodin perchlorate inhibits osteoclastogenesis through repressing RANKL-stimulated NFATc1 activity'. Together they form a unique fingerprint.

Cite this